| 名称 | Depatuxizumab MMAE |
| 描述 | Depatuxizumab MMAE is an antibody-drug conjugate (ADC) composed of the anti-EGFR monoclonal antibody depatuxizumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). This ADC effectively suppresses the growth of xenograft models harboring both mutant EGFRvIII and wild-type EGFR [1]. |
| 存储条件 | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 关键字 | AntibodyDrugConjugates(ADCs) | AntibodyDrugConjugates | AntibodyDrug Conjugates (ADCs) | Antibody-Drug Conjugates | ADCs |
| 相关产品 | PF-06647263 | DEDN6526A | Belantamab mafodotin | Brentuximab vedotin | Datopotamab deruxtecan | Telisotuzumab vedotin | Disitamab vedotin | Enfortumab vedotin-ejfv | Glembatumumab vedotin | Izeltabart Tapatansine | Sacituzumab govitecan | Trastuzumab deruxtecan |
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的，不可用于人类或动物的临床诊断、治疗或实验，不可药用，不可食用。
Copyright© 2022-2026 上海捷世凯生物科技有限公司 版权所有，All Rights Reserved 沪ICP备2022023965号
沪公网安备 31012002005937 
许可证编号：沪（奉）应急管危经许[2025]203724
主管 朱如燕 13795461237
售后 全香 15901740225
销售 郭佳宁 15001810326
微信公众号
